Allos Therapeutics — Merger or Acquisition (September 2011)
16 slides from Allos Therapeutics's merger presentation, Sep 30, 2011
Slide 1: AMAG Pharmaceuticals, Inc. Fall 2011
AMAG Pharmaceuticals, Inc. FALL 2011 1
Slide 2: Forward-looking Statements
Forward-looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, our s
Slide 3: Important Merger Information and Additional Information and Where to Find It
Important Merger Information and Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. The proposed merger between AMAG and Allos will be submitted to the re
Slide 4: Deal Background
Deal Background AMAG Board of Directors met in December 2010 and discussed the company’s business and strategy Determined that the company should pursue two parallel paths to enhance long-term stockholder value – the sale of the company and/or a transformative strategic acquisition Engaged Morgan St
Slide 5: Merger Highlights
Merger Highlights 5 Terms Stock for stock transaction Allos stockholders will receive 0.1282 AMAG shares for each Allos share held Ownership at Closing AMAG 61% / Allos 39% 2010 Product Revenues Feraheme 2010 net product revenues: $59.3 million Folotyn 2010 net product revenues: $35.2 million Cash P
Slide 6: NewCo: Improving Patient's Lives and Enhancing Value for Stockholders
NewCo: Improving Patient’s Lives and Enhancing Value for Stockholders 6
Slide 7: NewCo – Two Commercial Products Provide Solid Foundation for Growth
NewCo – Two Commercial Products Provide Solid Foundation for Growth 7
Slide 8: Feraheme and Folotyn Overview
FERAHEME FOLOTYN Description Therapeutic iron formulation delivered via intravenous (IV) injection Folate analogue metabolic inhibitor delivered via intravenous (IV) injection Labeled Indication Approved in June 2009 for the treatment of iron deficiency anemia (IDA) in adult patients with chronic ki
Slide 9: Feraheme and Folotyn: Attractive Opportunities for Continued Growth
Feraheme and Folotyn: Attractive Opportunities for Continued Growth 9 Market detail Non-dialysis CKD Incidence The overall U.S. non-dialysis IV iron market is estimated to be $400 million 1.6 million Americans are estimated to have non-dialysis dependent CKD and IDA, a fraction of which are treated
Slide 10: Multiple Milestones Provide Future Growth Opportunities
Multiple Milestones Provide Future Growth Opportunities 2011 Milestones Feraheme Second source manufacturing approved Decision expected regarding Canadian regulatory application for IDA in CKD Folotyn Initiate Phase 3 study in newly diagnosed PTCL patients; SPA agreement with FDA in place – first pa
Slide 11: Strategic Rationale of Merger
Strategic Rationale of Merger First step in building a profitable specialty pharmaceutical company focused on hematology and oncology Overlapping call points in hematology/oncology and hospitals provide enhanced access for Feraheme Largest non-dialysis CKD market segments for IV iron today Folotyn s
Slide 12: NewCo Financial Rationale
NewCo Financial Rationale Conservative combined net product revenues in 2013 of at least $125 million Assuming current US labels/indications for Folotyn and Feraheme, and EU and Canadian approval for Feraheme for CKD NewCo cash operating expenses in 2013 expected to be no greater than $120 million (
Slide 13: NewCo Expected to Realize Annual Synergies of $55 to $60 Million
NewCo Expected to Realize Annual Synergies of $55 to $60 Million Expected Annual Synergies Primary Driver Selling, General and Administrative (includes facilities rationalization) $38 mm - $41 mm Rationalization of redundant public company expenses Rationalization of redundant personnel, including f
Slide 14: Potential Financial Upside
Potential Financial Upside Revenues Feraheme CKD and Folotyn revenue synergies through expanded share of voice and access Feraheme sales from US IDA approval/launch Folotyn sales from label expansions (first-line PTCL and rrCTCL) Folotyn use derived from results of investigator sponsored research Ro
Slide 15: Focused on Building Long-term Value for Shareholders
Focused on Building Long-term Value for Shareholders We believe the merger with Allos Therapeutics Expands access to hematology/oncology for Feraheme in CKD and broad IDA indications Leverages existing commercial infrastructure and cost-base in hematology/oncology space Spreads public company costs
Slide 16: Thank You
Thank You INVESTOR CONTACT: 617-498-3361 16
Allos Therapeutics — Merger or Acquisition (September 2011) on 6ix